Erlotiniblet) and malignant neoplasm progression Patient Reports February 11, 2012

Erlotiniblet) Side Effects Report #5194494-4
Erlotiniblet) side effect was reported by a Physician from HONG KONG on Dec 18, 2006. Female patient, 72 years of age, was diagnosed with non-small cell lung cancer and was treated with Erlotiniblet). After drug was administered, patient experienced the following side effects: cardio-respiratory arrest, duodenal ulcer perforation, malignant neoplasm progression, pneumoperitoneum. Erlotiniblet) dosage: 150 MG (QD), ORAL. Patient was hospitalized. Patient died on 02/23/2006.